Adaptive therapy is a dynamic cancer treatment protocol that updates (or ‘adapts’) treatment decisions in anticipation of evolving tumor dynamics. This broad term encompasses many possible dynamic treatment protocols of patient-specific dose modulation or dose timing. Adaptive therapy maintains high levels of tumor burden to benefit from the competitive suppression of treatment-sensitive subpopulations on treatment-resistant subpopulations. This evolution-based approach to cancer treatment has been integrated into several ongoing or planned clinical trials, including treatment of metastatic castrate resistant prostate cancer, ovarian cancer, and BRAF-mutant melanoma. In the previous few decades, experimental and clinical investigation of adaptive therapy has progressed synergistically with mathematical and computational modeling. In this work, we discuss 11 open questions in cancer adaptive therapy mathematical modeling. The questions are split into three sections: (1) integrating the appropriate components into mathematical models (2) design and validation of dosing protocols, and (3) challenges and opportunities in clinical translation.
Adaptive therapy is an evolution-based treatment approach that aims to maintain tumor volume by employing minimum effective drug doses or timed drug holidays. For successful adaptive therapy outcomes, it is critical to find the optimal timing of treatment switch points in a patient-specific manner. Here we develop a combination of mathematical models that examine interactions between drug-sensitive and resistant cells to facilitate melanoma adaptive therapy dosing and switch time points. The first model assumes genetically fixed drug-sensitive and -resistant popul tions that compete for limited resources. The second model considers phenotypic switching between drug-sensitive and -resistant cells. We calibrated each model to fit melanoma patient biomarker changes over time and predicted patient-specific adaptive therapy schedules. Overall, the models predict that adaptive therapy would have delayed time to progression by 6–25 months compared to continuous therapy with dose rates of 6–74% relative to continuous therapy. We identified predictive factors driving the clinical time gained by adaptive therapy, such as the number of initial sensitive cells, competitive effect, switching rate from resistant to sensitive cells, and sensitive cell growth rate. This study highlights that there is a range of potential patient-specific benefits of adaptive therapy and identifies parameters that modulate this benefit.
During the last decade, our understanding of cancer cell signaling networks has significantly improved, leading to the development of various targeted therapies that have elicited profound but, unfortunately, short-lived responses. This is, in part, due to the fact that these targeted therapies ignore context and average out heterogeneity. Here, we present a mathematical framework that addresses the impact of signaling heterogeneity on targeted therapy outcomes. We employ a simplified oncogenic rat sarcoma (RAS)-driven mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase-protein kinase B (PI3K-AKT) signaling pathway in lung cancer as an experimental model system and develop a network model of the pathway. We measure how inhibition of the pathway modulates protein phosphorylation as well as cell viability under different microenvironmental conditions. Training the model on this data using Monte Carlo simulation results in a suite of in silico cells whose relative protein activities and cell viability match experimental observation. The calibrated model predicts distributional responses to kinase inhibitors and suggests drug resistance mechanisms that can be exploited in drug combination strategies. The suggested combination strategies are validated using in vitro experimental data. The validated in silico cells are further interrogated through an unsupervised clustering analysis and then integrated into a mathematical model of tumor growth in a homogeneous and resource-limited microenvironment. We assess posttreatment heterogeneity and predict vast differences across treatments with similar efficacy, further emphasizing that heterogeneity should modulate treatment strategies. The signaling model is also integrated into a hybrid cellular automata (HCA) model of tumor growth in a spatially heterogeneous microenvironment. As a proof of concept, we simulate tumor responses to targeted therapies in a spatially segregated tissue structure containing tumor and stroma (derived from patient tissue) and predict complex cell signaling responses that suggest a novel combination treatment strategy. A signaling pathway is a network of molecules in a cell that is typically initiated by stimuli (e.g., microenvironmental cues) acting on receptors and internal signaling molecules to determine cell fate. Signaling pathways in cancer cells are different from those in normal cells, and this difference helps cancer cells to grow and thrive indefinitely. Drugs that target the aberrant signaling pathways in cancer cells (often referred to as targeted therapy) are promising for improving treatment outcomes of many different cancers in patients. However, most patients eventually develop resistance to these drugs. Resistance may already be present in the tumor or may emerge via mutation or via microenvironmental mediation. Tumor heterogeneity, which is characterized by subtle or dramatic differences among tumor cells, plays a key role in the development of drug resistance. Some tumor cells respond well to therapy, while others may adapt to the stress induced by the drug within the microenvironment. Moreover, removal of drug-sensitive cells may result in the competitive release of drug-resistant cells. Here, we present mathematical models to assess the impact of heterogeneity in signaling pathways within tumor cells on the outcomes of targeted therapy. We consider a simplified version of two well-known signaling pathways that modulate the growth of lung cancer cells. By using different targeted therapies, we quantify the effect of pathway inhibition on protein activity and cell viability and developed a mathematical model of the network, which is trained to reproduce these data and to develop a panel of heterogeneous in silico cells. The model predicts potential mechanisms of drug resistance and proposes combination therapies that are effective across the panel. We validate these combination therapies experimentally using the lung cancer cells and integrated the in silico cells into a computational lung tissue model that explicitly captures the microenvironment of lung cancer. Our results suggest that heterogeneity in both the tumor and microenvironment impacts treatment response in different ways and suggest a novel combination therapy for a better response.
• We present a mathematical model driven framework for virtual clinical trials (phase i trials). • The phase i trial paradigm: model development, cohort generation, stratification, and optimizing treatment schedules. • Phase i trial in melanoma captured the observed heterogeneity of patient responses to treatment. • Phase i trial stratified cohort predicts main differentiators of patient survival. • Model predicted optimal treatment schedule not only improved survival but also decreased toxicity.
The novel coronavirus disease (COVID-19) poses a severe threat to public health officials all around the world. The early COVID-19 outbreak in South Korea displayed significant spatial heterogeneity. The number of confirmed cases increased rapidly in the Daegu and Gyeongbuk (epicenter), whereas the spread was much slower in the rest of Korea. A two-patch mathematical model with a mobility matrix is developed to capture this significant spatial heterogeneity of COVID-19 outbreaks from 18 February to 24 March 2020. The mobility matrix is taken from the movement data provided by the Korea Transport Institute (KOTI). Some of the essential patch-specific parameters are estimated through cumulative confirmed cases, including the transmission rates and the basic reproduction numbers (local and global). Our simulations show that travel restrictions between the epicenter and the rest of Korea effectively prevented massive outbreaks in the rest of Korea. Furthermore, we explore the effectiveness of several additional strategies for the mitigation and suppression of Covid-19 spread in Korea, such as implementing social distancing and early diagnostic interventions.